Additionally, 10 of the 11 patients with a measurable central nervous system metastasis at enrollment in the LIBRETTO-001 trial showed a successful therapeutic response, highlighting the blood–brain barrier permeability of next generation kinase inhibitors and further supporting a role for RET inhibitor treatment in brain-metastatic breast cancer [97]. Here, RET is linked to breast carcinoma.